Splash Beverage Group shares are trading lower. The company announced an exclusive global licensing agreement with Argent BioPharma for epilepsy therapy CannEpil.

Benzinga Newsdesk www.benzinga.com Positive 71.6%

Neg 0% Neu 0% Pos 71.6%

Comments

No comments yet. Be the first!